ArticlePediatric surgery international2026
Comparison of non-invasive liver fibrosis indicators for biliary atresia.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo compare the value of non-invasive liver fibrosis indicators, including serum matrix metalloproteinase-7 (MMP-7), APRI, collagen-related proteins [hyaluronic acid (HA), type IV collagen (IV-C), type III procollagen N-terminal peptide (PIIIP), laminin] and shear wave elastography (SWE), in assessing liver fibrosis for biliary atresia (BA).
methodsA retrospective cohort study was conducted in BA infants from July 2020 to December 2023. Liver fibrosis was classified according to the Batts-Ludwig criteria.
resultsA total of 471 BA infants were included. Serum MMP-7, HA, IV-C, PIIIP, laminin, and SWE all correlated with liver fibrosis, with correlation coefficients of 0.4, 0.28, 0.37, -0.15, 0.16, and 0.46 (all P < 0.01), respectively. For severe fibrosis, the AUROC was 0.675 (95% CI: 0.622-0.728) at a cutoff value of 58.98 ng/ml for MMP-7, 0.719 (95% CI: 0.664-0.775) at a cutoff value of 547.05 for IV-C, and 0.732 (95% CI: 0.667-0.796) at a cutoff value of 1.35 m/s for SWE. Among the combined models, IV-C + MMP-7 achieved the higher performance (AUROC 0.756, 95% CI 0.700-0.811).
conclusionsNon-invasive serum markers and SWE all showed moderate value for fibrosis assessment in BA. SWE may be a promising and useful non-invasive tool, while selected serum biomarker combinations may provide complementary value for identifying severe fibrosis.
Indexed as
Identifiers
42257719What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.